CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells

Gwenola Manic, Michele Signore, Antonella Sistigu, Giorgio Russo, Francesca Corradi, Silvia Siteni, Martina Musella, Sara Vitale, Maria Laura De Angelis, Matteo Pallocca, Carla Azzurra Amoreo, Francesca Sperati, Simone Di Franco, Sabina Barresi, Eleonora Policicchio, Gabriele De Luca, Francesca De Nicola, Marcella Mottolese, Ann Zeuner, Maurizio FanciulliGiorgio Stassi, Marcello Maugeri-Saccà, Marta Baiocchi, Marco Tartaglia, Ilio Vitale, Ruggero De Maria

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: Cancer stem cells (CSCs) are responsible for tumour formation and spreading, and their targeting is required for tumour eradication. There are limited therapeutic options for advanced colorectal cancer (CRC), particularly for tumours carrying RAS-activating mutations. The aim of this study was to identify novel CSC-targeting strategies. Design: To discover potential therapeutics to be clinically investigated as single agent, we performed a screening with a panel of FDA-approved or investigational drugs on primary CRC cells enriched for CSCs (CRC-SCs) isolated from 27 patients. Candidate predictive biomarkers of efficacy were identified by integrating genomic, reverse-phase protein microarray (RPPA) and cytogenetic analyses, and validated by immunostainings. DNA replication stress (RS) was increased by employing DNA replication-perturbing or polyploidising agents. Results: The drug-library screening led to the identification of LY2606368 as a potent anti-CSC agent acting in vitro and in vivo in tumour cells from a considerable number of patients (∼36%). By inhibiting checkpoint kinase (CHK)1, LY2606368 affected DNA replication in most CRC-SCs, including RAS-mutated ones, forcing them into premature, lethal mitoses. Parallel genomic, RPPA and cytogenetic analyses indicated that CRC-SCs sensitive to LY2606368 displayed signs of ongoing RS response, including the phosphorylation of RPA32 and ataxia telangiectasia mutated serine/threonine kinase (ATM). This was associated with mutation(s) in TP53 and hyperdiploidy, and made these CRC-SCs exquisitely dependent on CHK1 function. Accordingly, experimental increase of RS sensitised resistant CRC-SCs to LY2606368. Conclusions: LY2606368 selectively eliminates replication-stressed, p53-deficient and hyperdiploid CRC-SCs independently of RAS mutational status. These results provide a strong rationale for biomarker-driven clinical trials with LY2606368 in patients with CRC.

Original languageEnglish
Pages (from-to)903-917
Number of pages15
JournalGut
Volume67
Issue number5
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Polyploidy
Neoplastic Stem Cells
DNA Replication
Colorectal Neoplasms
Protein Array Analysis
Therapeutics
Cytogenetic Analysis
Neoplasms
Biomarkers
Investigational Drugs
Ataxia Telangiectasia
Mutation
Preclinical Drug Evaluations
Protein-Serine-Threonine Kinases
Mitosis
Phosphorylation
Clinical Trials

Keywords

  • CELL CYCLE CONTROL
  • CHEMOTHERAPY
  • COLORECTAL CANCER
  • DNA DAMAGE
  • DRUG DEVELOPMENT

ASJC Scopus subject areas

  • Gastroenterology

Cite this

CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. / Manic, Gwenola; Signore, Michele; Sistigu, Antonella; Russo, Giorgio; Corradi, Francesca; Siteni, Silvia; Musella, Martina; Vitale, Sara; De Angelis, Maria Laura; Pallocca, Matteo; Amoreo, Carla Azzurra; Sperati, Francesca; Di Franco, Simone; Barresi, Sabina; Policicchio, Eleonora; De Luca, Gabriele; De Nicola, Francesca; Mottolese, Marcella; Zeuner, Ann; Fanciulli, Maurizio; Stassi, Giorgio; Maugeri-Saccà, Marcello; Baiocchi, Marta; Tartaglia, Marco; Vitale, Ilio; De Maria, Ruggero.

In: Gut, Vol. 67, No. 5, 01.05.2018, p. 903-917.

Research output: Contribution to journalArticle

Manic, G, Signore, M, Sistigu, A, Russo, G, Corradi, F, Siteni, S, Musella, M, Vitale, S, De Angelis, ML, Pallocca, M, Amoreo, CA, Sperati, F, Di Franco, S, Barresi, S, Policicchio, E, De Luca, G, De Nicola, F, Mottolese, M, Zeuner, A, Fanciulli, M, Stassi, G, Maugeri-Saccà, M, Baiocchi, M, Tartaglia, M, Vitale, I & De Maria, R 2018, 'CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells', Gut, vol. 67, no. 5, pp. 903-917. https://doi.org/10.1136/gutjnl-2016-312623
Manic, Gwenola ; Signore, Michele ; Sistigu, Antonella ; Russo, Giorgio ; Corradi, Francesca ; Siteni, Silvia ; Musella, Martina ; Vitale, Sara ; De Angelis, Maria Laura ; Pallocca, Matteo ; Amoreo, Carla Azzurra ; Sperati, Francesca ; Di Franco, Simone ; Barresi, Sabina ; Policicchio, Eleonora ; De Luca, Gabriele ; De Nicola, Francesca ; Mottolese, Marcella ; Zeuner, Ann ; Fanciulli, Maurizio ; Stassi, Giorgio ; Maugeri-Saccà, Marcello ; Baiocchi, Marta ; Tartaglia, Marco ; Vitale, Ilio ; De Maria, Ruggero. / CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. In: Gut. 2018 ; Vol. 67, No. 5. pp. 903-917.
@article{27d9cd29cea64ae092097cd2cff312c5,
title = "CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells",
abstract = "Objective: Cancer stem cells (CSCs) are responsible for tumour formation and spreading, and their targeting is required for tumour eradication. There are limited therapeutic options for advanced colorectal cancer (CRC), particularly for tumours carrying RAS-activating mutations. The aim of this study was to identify novel CSC-targeting strategies. Design: To discover potential therapeutics to be clinically investigated as single agent, we performed a screening with a panel of FDA-approved or investigational drugs on primary CRC cells enriched for CSCs (CRC-SCs) isolated from 27 patients. Candidate predictive biomarkers of efficacy were identified by integrating genomic, reverse-phase protein microarray (RPPA) and cytogenetic analyses, and validated by immunostainings. DNA replication stress (RS) was increased by employing DNA replication-perturbing or polyploidising agents. Results: The drug-library screening led to the identification of LY2606368 as a potent anti-CSC agent acting in vitro and in vivo in tumour cells from a considerable number of patients (∼36{\%}). By inhibiting checkpoint kinase (CHK)1, LY2606368 affected DNA replication in most CRC-SCs, including RAS-mutated ones, forcing them into premature, lethal mitoses. Parallel genomic, RPPA and cytogenetic analyses indicated that CRC-SCs sensitive to LY2606368 displayed signs of ongoing RS response, including the phosphorylation of RPA32 and ataxia telangiectasia mutated serine/threonine kinase (ATM). This was associated with mutation(s) in TP53 and hyperdiploidy, and made these CRC-SCs exquisitely dependent on CHK1 function. Accordingly, experimental increase of RS sensitised resistant CRC-SCs to LY2606368. Conclusions: LY2606368 selectively eliminates replication-stressed, p53-deficient and hyperdiploid CRC-SCs independently of RAS mutational status. These results provide a strong rationale for biomarker-driven clinical trials with LY2606368 in patients with CRC.",
keywords = "CELL CYCLE CONTROL, CHEMOTHERAPY, COLORECTAL CANCER, DNA DAMAGE, DRUG DEVELOPMENT",
author = "Gwenola Manic and Michele Signore and Antonella Sistigu and Giorgio Russo and Francesca Corradi and Silvia Siteni and Martina Musella and Sara Vitale and {De Angelis}, {Maria Laura} and Matteo Pallocca and Amoreo, {Carla Azzurra} and Francesca Sperati and {Di Franco}, Simone and Sabina Barresi and Eleonora Policicchio and {De Luca}, Gabriele and {De Nicola}, Francesca and Marcella Mottolese and Ann Zeuner and Maurizio Fanciulli and Giorgio Stassi and Marcello Maugeri-Sacc{\`a} and Marta Baiocchi and Marco Tartaglia and Ilio Vitale and {De Maria}, Ruggero",
year = "2018",
month = "5",
day = "1",
doi = "10.1136/gutjnl-2016-312623",
language = "English",
volume = "67",
pages = "903--917",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells

AU - Manic, Gwenola

AU - Signore, Michele

AU - Sistigu, Antonella

AU - Russo, Giorgio

AU - Corradi, Francesca

AU - Siteni, Silvia

AU - Musella, Martina

AU - Vitale, Sara

AU - De Angelis, Maria Laura

AU - Pallocca, Matteo

AU - Amoreo, Carla Azzurra

AU - Sperati, Francesca

AU - Di Franco, Simone

AU - Barresi, Sabina

AU - Policicchio, Eleonora

AU - De Luca, Gabriele

AU - De Nicola, Francesca

AU - Mottolese, Marcella

AU - Zeuner, Ann

AU - Fanciulli, Maurizio

AU - Stassi, Giorgio

AU - Maugeri-Saccà, Marcello

AU - Baiocchi, Marta

AU - Tartaglia, Marco

AU - Vitale, Ilio

AU - De Maria, Ruggero

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Objective: Cancer stem cells (CSCs) are responsible for tumour formation and spreading, and their targeting is required for tumour eradication. There are limited therapeutic options for advanced colorectal cancer (CRC), particularly for tumours carrying RAS-activating mutations. The aim of this study was to identify novel CSC-targeting strategies. Design: To discover potential therapeutics to be clinically investigated as single agent, we performed a screening with a panel of FDA-approved or investigational drugs on primary CRC cells enriched for CSCs (CRC-SCs) isolated from 27 patients. Candidate predictive biomarkers of efficacy were identified by integrating genomic, reverse-phase protein microarray (RPPA) and cytogenetic analyses, and validated by immunostainings. DNA replication stress (RS) was increased by employing DNA replication-perturbing or polyploidising agents. Results: The drug-library screening led to the identification of LY2606368 as a potent anti-CSC agent acting in vitro and in vivo in tumour cells from a considerable number of patients (∼36%). By inhibiting checkpoint kinase (CHK)1, LY2606368 affected DNA replication in most CRC-SCs, including RAS-mutated ones, forcing them into premature, lethal mitoses. Parallel genomic, RPPA and cytogenetic analyses indicated that CRC-SCs sensitive to LY2606368 displayed signs of ongoing RS response, including the phosphorylation of RPA32 and ataxia telangiectasia mutated serine/threonine kinase (ATM). This was associated with mutation(s) in TP53 and hyperdiploidy, and made these CRC-SCs exquisitely dependent on CHK1 function. Accordingly, experimental increase of RS sensitised resistant CRC-SCs to LY2606368. Conclusions: LY2606368 selectively eliminates replication-stressed, p53-deficient and hyperdiploid CRC-SCs independently of RAS mutational status. These results provide a strong rationale for biomarker-driven clinical trials with LY2606368 in patients with CRC.

AB - Objective: Cancer stem cells (CSCs) are responsible for tumour formation and spreading, and their targeting is required for tumour eradication. There are limited therapeutic options for advanced colorectal cancer (CRC), particularly for tumours carrying RAS-activating mutations. The aim of this study was to identify novel CSC-targeting strategies. Design: To discover potential therapeutics to be clinically investigated as single agent, we performed a screening with a panel of FDA-approved or investigational drugs on primary CRC cells enriched for CSCs (CRC-SCs) isolated from 27 patients. Candidate predictive biomarkers of efficacy were identified by integrating genomic, reverse-phase protein microarray (RPPA) and cytogenetic analyses, and validated by immunostainings. DNA replication stress (RS) was increased by employing DNA replication-perturbing or polyploidising agents. Results: The drug-library screening led to the identification of LY2606368 as a potent anti-CSC agent acting in vitro and in vivo in tumour cells from a considerable number of patients (∼36%). By inhibiting checkpoint kinase (CHK)1, LY2606368 affected DNA replication in most CRC-SCs, including RAS-mutated ones, forcing them into premature, lethal mitoses. Parallel genomic, RPPA and cytogenetic analyses indicated that CRC-SCs sensitive to LY2606368 displayed signs of ongoing RS response, including the phosphorylation of RPA32 and ataxia telangiectasia mutated serine/threonine kinase (ATM). This was associated with mutation(s) in TP53 and hyperdiploidy, and made these CRC-SCs exquisitely dependent on CHK1 function. Accordingly, experimental increase of RS sensitised resistant CRC-SCs to LY2606368. Conclusions: LY2606368 selectively eliminates replication-stressed, p53-deficient and hyperdiploid CRC-SCs independently of RAS mutational status. These results provide a strong rationale for biomarker-driven clinical trials with LY2606368 in patients with CRC.

KW - CELL CYCLE CONTROL

KW - CHEMOTHERAPY

KW - COLORECTAL CANCER

KW - DNA DAMAGE

KW - DRUG DEVELOPMENT

UR - http://www.scopus.com/inward/record.url?scp=85046478182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046478182&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2016-312623

DO - 10.1136/gutjnl-2016-312623

M3 - Article

AN - SCOPUS:85046478182

VL - 67

SP - 903

EP - 917

JO - Gut

JF - Gut

SN - 0017-5749

IS - 5

ER -